细胞周期停滞生物标志物预测急性肾损伤后肾功能恢复:一项前瞻性验证研究
本研究前瞻性连续纳入379例入住ICU后发生AKI的危重患者,分推导队列(194例)和验证队列(185例),在AKI诊断当时(第0天)和24小时后(第1天)检测尿TIMP-2与IGFBP7。379例中159例(41.9%)在7天内未恢复肾功能(推导队列79例、验证队列80例)。第0天尿[TIMP-2]*[IGFBP7]预测不恢复的AUC为0.751(95%CI 0.701-0.852,p<0.001),最佳截断值1.05 (ng/mL)²/1000;联合尿量标准诊断AKI、AKI 2-3期和非肾SOFA评分后AUC提高至0.852(95%CI 0.750-0.891,p<0.001),敏感度88.8%(72.9,98.7)、特异度92.6%(80.8,100.0)。第1天各标志物预测恢复的能力均较差。
要点
- 379例ICU后AKI患者中159例(41.9%)7天内未恢复,推导队列79例、验证队列80例。
- 第0天尿[TIMP-2]*[IGFBP7]预测不恢复AUC 0.751(95%CI 0.701-0.852,p<0.001),最佳截断值1.05 (ng/mL)²/1000。
- 联合尿量标准诊断AKI、AKI 2-3期和非肾SOFA评分后AUC 0.852(95%CI 0.750-0.891,p<0.001),敏感度88.8%(72.9,98.7)、特异度92.6%(80.8,100.0)。
- 第1天尿[TIMP-2]*[IGFBP7]、单测TIMP-2和单测IGFBP7预测AKI恢复的能力均较差。
- 第0天[TIMP-2]*[IGFBP7]对不恢复的预测能力优于单测TIMP-2或IGFBP7。
适用人群与场景
- 入住ICU后发生AKI的危重患者,前瞻性连续纳入379例,分推导队列194例和验证队列185例。
诊断标准与关键阈值
- AKI诊断标准及分期依据原文提及的尿量(UO)标准和AKI 2-3期分层。
- 第0天尿[TIMP-2]*[IGFBP7]预测AKI不恢复的最佳截断值为1.05 (ng/mL)²/1000。
研究设计与关键结果
- 前瞻性验证研究,纳入379例ICU后AKI患者,分推导队列(194例)和验证队列(185例)。
- 主要终点为7天内AKI不恢复;379例中159例(41.9%)未恢复,推导队列79例、验证队列80例。
- 第0天尿[TIMP-2]*[IGFBP7]预测不恢复AUC 0.751(95%CI 0.701-0.852,p<0.001),最佳截断值1.05 (ng/mL)²/1000,优于单测TIMP-2和IGFBP7。
- 第0天[TIMP-2]*[IGFBP7]联合尿量标准诊断AKI、AKI 2-3期和非肾SOFA评分后AUC 0.852(95%CI 0.750-0.891,p<0.001),敏感度88.8%(72.9,98.7)、特异度92.6%(80.8,100.0)。
- 第1天尿[TIMP-2]*[IGFBP7]、单测TIMP-2和单测IGFBP7预测AKI恢复的能力均较差。
证据类型、等级与局限
- 证据类型:前瞻性验证研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对ICU后发生AKI的患者,可在诊断当时(第0天)检测尿[TIMP-2]*[IGFBP7],以1.05 (ng/mL)²/1000为截断值辅助识别7天内可能不恢复者。
- 将第0天尿[TIMP-2]*[IGFBP7]与尿量标准诊断AKI、AKI 2-3期和非肾SOFA评分联合,可提高预测不恢复的准确度(AUC 0.852)。
- 第1天检测[TIMP-2]*[IGFBP7]、TIMP-2或IGFBP7对预测AKI恢复价值有限。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute kidney injury (AKI) is a common disease in the intensive care unit (ICU). AKI patients with nonrecovery of renal function have a markedly increased risk of death compared with patients with recovery. The current study aimed to explore and validate the utility of urinary cell cycle arrest biomarkers for predicting nonrecovery in patients who developed AKI after ICU admission.
METHODS: We prospectively and consecutively enrolled 379 critically ill patients who developed AKI after admission to the ICU, which were divided into a derivation cohort (194 AKI patients) and a validation cohort (185 AKI patients). The biomarkers of urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) were detected at inclusion immediately after AKI diagnosis (day 0) and 24 h later (day 1). The optimal cut-off values of these biomarkers for predicting nonrecovery were estimated in the derivation cohort, and their predictive accuracy was assessed in the validation cohort. The primary endpoint was nonrecovery from AKI (within 7 days).
RESULTS: Of 379 patients, 159 (41.9%) patients failed to recover from AKI onset, with 79 in the derivation cohort and 80 in the validation cohort. Urinary [TIMP-2]*[IGFBP7] on day 0 showed a better prediction ability for nonrecovery than TIMP-2 and IGFBP7 alone, with an area under the reciever operating characteristic curve (AUC) of 0.751 [95% confidence interval (CI) 0.701-0.852, p < 0.001] and an optimal cut-off value of 1.05 ((ng/mL)2/1000). When [TIMP-2]*[IGFBP7] was combined with the clinical factors of AKI diagnosed by the urine output (UO) criteria, AKI stage 2-3 and nonrenal SOFA score for predicting nonrecovery, the AUC was significantly improved to 0.852 (95% CI 0.750-0.891, p < 0.001), which achieved a sensitivity and specificity of 88.8% (72.9, 98.7) and 92.6% (80.8, 100.0), respectively. However, urine [TIMP-2]*[IGFBP7], TIMP-2 alone, and IGFBP7 alone on day 1 performed poorly for predicting AKI recovery.
CONCLUSION: Urinary [TIMP-2]*[IGFBP7] on day 0 showed a fair performance for predicting nonrecovery from AKI. The predictive accuracy can be improved when urinary [TIMP-2]*[IGFBP7] is combined with the clinical factors of AKI diagnosed by the UO criteria, AKI stage 2-3 and nonrenal SOFA score.
参考来源
- Jia HM, Cheng L, Weng YB, et al. Cell cycle arrest biomarkers for predicting renal recovery from acute kidney injury: a prospective validation study. Ann Intensive Care. 2022. PMID: 35150348. doi:10.1186/s13613-022-00989-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。